Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of "Moderate Buy" by Analysts

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eleven brokerages that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $27.38.

Several equities research analysts have weighed in on the stock. Scotiabank decreased their price target on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research note on Wednesday, January 8th. Jefferies Financial Group cut their price target on Kura Oncology from $32.00 to $28.00 and set a "buy" rating on the stock in a report on Thursday, November 21st. HC Wainwright upped their target price on Kura Oncology from $32.00 to $37.00 and gave the stock a "buy" rating in a research report on Thursday, November 21st. Stifel Nicolaus downgraded shares of Kura Oncology from a "buy" rating to a "hold" rating and reduced their price target for the company from $26.00 to $19.00 in a research report on Monday, October 14th. Finally, Wedbush restated an "outperform" rating and set a $37.00 price objective on shares of Kura Oncology in a report on Monday, November 4th.

Kura Oncology Trading Down 2.9 %

Shares of Kura Oncology stock traded down $0.23 on Friday, hitting $7.98. 687,832 shares of the company's stock traded hands, compared to its average volume of 1,484,396. The company has a fifty day moving average of $9.88 and a two-hundred day moving average of $16.09. Kura Oncology has a one year low of $6.98 and a one year high of $24.17. The company has a market capitalization of $620.21 million, a price-to-earnings ratio of -3.39 and a beta of 0.81. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.64) by $0.01. During the same period in the prior year, the firm earned ($0.50) EPS. As a group, sell-side analysts expect that Kura Oncology will post -2.44 earnings per share for the current year.

Institutional Trading of Kura Oncology

Several institutional investors have recently made changes to their positions in KURA. nVerses Capital LLC purchased a new position in Kura Oncology during the third quarter worth about $25,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Kura Oncology by 11.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company's stock worth $144,000 after buying an additional 1,750 shares in the last quarter. Point72 DIFC Ltd bought a new position in shares of Kura Oncology in the third quarter valued at approximately $146,000. Quarry LP purchased a new stake in shares of Kura Oncology during the second quarter valued at approximately $196,000. Finally, Erste Asset Management GmbH purchased a new stake in shares of Kura Oncology during the third quarter valued at approximately $215,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.